/ RoW:Low 20% of net salesProfit ShareChina:50/50 profit shareEquity Investment$20.0M*****A $62 million time-based development milestone became non-contingent as of July 30, 2014**Includes 50% of U.S. costs under agreed development plan***Includes U.S. and Europe costs not borne by Astellas; $116.5 million is less than 50% of the expected CKD anemia development costs****Concurrent private placement of our common stock with an aggregate purchase price of $20 million at a price per share equal to the initial public offering priceIn addition, Astellas has separately invested a total of $80.5 million in the preferred stock of FibroGen, Inc. to date.-6-Table of ContentsRoxadustat for Treatment of Anemia in ChinaWe believe there is a particularly significant unmet medical need for the treatment of anemia in CKD in China.
States and potentially outside of the United States.•Continue to pursue an extensive and multi-layered patent portfolio to protect our technologies and product candidates.•Explore potential partnering opportunities for the development and commercialization of FG-3019 in certain territories.•Develop FG-5200 for treatment of corneal blindness resulting from partial thickness corneal damage in China and elsewhere in the world.•Strategically invest in the research and development of additional anemia indications for roxadustat, which may include chemotherapy-induced anemia, anemia relating to inflammatory diseases, myelodysplastic syndrome and
These risks include, among others, the following:•We have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future; we may require additional financings in order to fund our operations;•All of our recent revenue has been received from our roxadustat collaboration partners; if any of the agreements with these collaboration partners were to terminate we would require substantial additional funding;•If we are unable to achieve development and regulatory milestones under our collaboration agreements, our revenues may decrease and our activities may fail to lead to commercialized products;•We are substantially dependent on the success of our lead product candidate, roxadustat, and our second compound in development, FG-3019, and their clinical and commercial success will depend on a number of factors,
results, be able to achieve sufficient enrollment or be completed on schedule, if at all;•Our product candidates may cause, or have attributed to them, undesirable side effects or have other properties that delay or prevent their regulatory approval or limit their commercial potential;•If we or third party manufacturers on which we rely cannot manufacture our product candidates and/or products at sufficient yields, we may experience delays in development, regulatory approval and commercialization;-10-Table of Contents•If our collaborations with Astellas or AstraZeneca were terminated, or if Astellas of AstraZeneca were to prioritize other initiatives over their collaborations with us, whether as a result of a change of control or
otherwise, our ability to successfully develop and commercialize our lead product candidate, roxadustat, would suffer;•We currently rely, and expect to continue to rely, on third parties to conduct many aspects of our clinical studies, and these third parties may not perform satisfactorily;•Certain of the components of our product candidates are acquired from single-source suppliers and have been purchased without long-term supply agreements;•If our efforts to protect our proprietary technologies are not adequate, we may not be able to compete effectively in our market;•Intellectual property disputes with third parties and competitors may be costly and time consuming, and may negatively affect our competitive position;•We are establishing international operations and seeking approval to commercialize our product candidates outside of the United States, in particular in China, and a number of risks associated with international
manufacturing plant; accordingly, we cannot assure you we will be able to meet regulatory requirements to operate our plant and to sell our products;•Our decision to seek approval in China for roxadustat as a domestic new drug may not be accepted, which would result in additional delay and expense; and•The market price of our common stock may be highly volatile, and you may not be able to resell your shares at or above the initial public offering price.Concurrent Private PlacementAstraZeneca, one of our collaboration partners, has agreed to purchase from us concurrently with the closing of this offering in a private
become and remain profitable would depress the market price of our common stock and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations.We believe that we will continue to expend substantial resources for the foreseeable future as we continue late-stage clinical development of roxadustat, grow
our operations in China, expand our clinical development efforts on FG-3019, seek regulatory approval and prepare for the commercialization of our product candidates, and pursue additional indications.
capital due to favorable market conditions or strategic considerations even if we currently believe that we have sufficient funds for our current or future operating plans.Our future funding requirements will depend on many factors, including, but not limited to:•the rate of progress in the development of our product candidates;•the costs of development efforts for our product candidates, such as FG-3019, that are not subject to reimbursement from our collaboration partners;•the costs necessary to obtain regulatory approvals, if any, for our product candidates in the United States, China and other jurisdictions, and the costs of post-marketing studies that could be required by regulatory
authorities in jurisdictions where approval is obtained;•the continuation of our existing collaborations and entry into new collaborations;•the time and unreimbursed costs necessary to commercialize products in territories in which our product candidates are approved for sale;•the revenues from any future sales of our products as well as revenue earned from profit share, royalties and milestones;•the level of reimbursement or third party payor pricing available to our products;•the costs of establishing and maintaining manufacturing operations and obtaining third party commercial supplies of our products, if any, manufactured in accordance with regulatory requirements;•the costs we incur in maintaining domestic and foreign operations, including operations in China;•the costs associated with being a public company; and•the costs we incur in the filing, prosecution, maintenance and defense of our extensive patent portfolio and other intellectual property rights.Additional funds may not be available when we require them, or on terms that are acceptable to us.
anticipated demand at a cost that allows us to achieve profitability;•our success in educating health care providers and patients about the benefits, risks, administration and use of our product candidates, if approved;•acceptance of our product candidates, if approved, as safe and effective by patients and the healthcare community;•the success of efforts to enter into relationships with large dialysis organizations involving the administration of roxadustat to dialysis patients;•the achievement and maintenance of compliance with all regulatory requirements applicable to our product candidates;•the maintenance of an acceptable safety profile of our products following any approval;•the availability, perceived advantages, relative cost, relative safety, and relative efficacy of alternative and competitive treatments;•our ability to obtain and sustain an adequate level of pricing or reimbursement for our products by third party payors;•our ability to enforce successfully our intellectual property rights for our product candidates and against the products of potential competitors; and•our ability to avoid or succeed in third party patent interference or patent infringement claims.Many of
any of our product candidates if approved, the substantial cost and expense of complying with a REMS or other post-marketing requirements may limit our ability to successfully commercialize our product candidates.-22-Table of ContentsOur Phase 2 clinical trial results to date for roxadustat may not be indicative of the results that may be
terminated for a variety of reasons, including delay or failure to:•address any physician or patient safety concerns that arise during the course of the trial;•obtain required regulatory or institutional review board, or IRB, approval or guidance;-24-Table of Contents•reach timely agreement on acceptable terms with prospective CROs and clinical trial sites;•recruit, enroll and retain patients through the completion of the trial;•maintain clinical sites in compliance with clinical trial protocols;•initiate or add a sufficient number of clinical trial sites; and•manufacture sufficient quantities of product candidate for use in clinical trials.In addition, we could
through similar biological pathways may be deemed to be related to our product candidate and may result in:•our Phase 3 clinical trial development plan becoming longer and more extensive;•regulatory authorities increasing the data and information required to approve our product candidates and imposing other requirements; and•our collaboration partners terminating our existing agreements.The occurrence of any or all of these events
Market acceptance of any approved product depends on a number of other factors, including:•the clinical indications for which the product is approved and the labeling required by regulatory authorities for use with the product, including any warnings that may be required in the labeling;•acceptance by physicians and patients of the product as a safe and effective treatment and the willingness of the target patient population to try new therapies and of physicians to prescribe new therapies;•the cost, safety, efficacy and convenience of treatment in relation to alternative treatments;•the restrictions on the use of our products together with other medications, if any;•the availability of adequate coverage and reimbursement or pricing by third party payors and government authorities;•the ability of treatment providers, such as dialysis clinics, to enter into relationships with us without violating their existing agreement; and•the effectiveness of our sales and marketing efforts.For example, in the case of roxadustat, two of the